VivoSeq
Oncology

Cervix Cancer

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Cervix Cancer is an early-stage landscape with 0 programs across 1 company. The most active players are Belgian Gynaecological Oncology Group.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Belgian Gynaecological Oncology Group

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Withdrawn1 · 17%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries
Active, not recruiting·WWeill Medical College of Cornell University·Preclinical·NCT06002126·1,001 enrolled
Uniting Trusted Community Messengers to Improve Access to Cervical Cancer Screening in Rural North Carolina Aim 3
Not yet recruiting·UUNC Lineberger Comprehensive Cancer Center·Preclinical·NCT07294066·112 enrolled
ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer
Completed·BBelgian Gynaecological Oncology Group·Phase 2·NCT02009579·120 enrolled
CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
Completed·AARCAGY/ GINECO GROUP·Phase 1·NCT00251888·15 enrolled
Phase 0 Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer
Completed·—·N/A·NCT05462951·19 enrolled
Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Withdrawn·LLeo W. Jenkins Cancer Center·Phase 2·NCT00600210

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)